More Than 100 New Medicines in Development to Treat Mental Health Disorders - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

More Than 100 New Medicines in Development to Treat Mental Health Disorders



America’s biopharmaceutical research companies are developing 119 new medicines to help improve the lives of the estimated 61.5 million Americans that are affected by mental health disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

These medicines in development, all either in clinical trials or under review by FDA, include 36 for schizophrenia, 29 for depression, 20 for substance/addictive disorders, 15 for attention deficit/hyperactivity disorder, and 15 for anxiety disorders.

The new report outlines the numerous approaches being pursed to treat many of these disorders. Some examples include a medicine that may provide a broader spectrum of therapeutic activity for ADHD, an intranasal medicine for treatment-resistant depression that may offer a rapid onset of therapeutic effects, and a medicine for schizophrenia that potentially could result in fewer negative side effects than existing treatments.

Source: Pharmaceutical Research and Manufacturers of America

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here